Low-Sodium Oxybate

Low-sodium oxybate was chosen over sodium oxybate because it reduces sodium intake by 92%. Participants take low-sodium oxybate immediately before sleep because oxybate has a short half-life of about 30 to 60 minutes. The starting dose is 2 g at bedtime and is titrated weekly toward a 5 g target dose after 6 weeks. Valproic acid, phenytoin, ethosuximide, and topiramate may interact with low-sodium oxybate. Low-sodium oxybate is intended to deepen slow-wave sleep and thereby potentially stimulate glymphatic clearance. The trial uses XYWAV, an oral oxybate solution with lower sodium content than sodium oxybate.